Teva Pharmaceutical Industries vs Viatris
TEVA and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TEVA and VTRS compare
Teva Pharmaceutical Industries is the larger company, worth 2.1 times as much as Viatris ($50.9B against $23.9B).
Viatris grew revenue faster over the last twelve months (4.3% versus −15.2% for Teva Pharmaceutical Industries).
Viatris pays a dividend yielding 2.3%; Teva Pharmaceutical Industries does not pay one.
Teva Pharmaceutical Industries scores higher on the StockData Score (7 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TEVA | VTRS |
|---|---|---|
| Size and price | ||
| Market cap | $50.9B | $23.9B |
| Share price | $43.65 | $20.82 |
| Change, 1 year | 73.7% | 89.1% |
| Change, 5 years | 392% | 59.2% |
| Beta (5Y) | 0.98 | 0.86 |
| Employees | 34K | 30K |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 72.8× | – |
| P/S | 3.6× | 1.6× (better) |
| P/B | 6.6× | – |
| EV/EBITDA | 20.0× | 12.6× (better) |
| P/FCF | 37.7× | 11.3× (better) |
| FCF yield | 2.7% | 8.8% (better) |
| Fair value | $19.90 | $23.22 |
| Margin of safety | −119% | 10.4% (better) |
| Growth | ||
| Revenue growth (TTM) | −15.2% | 4.3% (better) |
| Revenue growth, 5Y average | 0.71% | 3.7% (better) |
| Profitability | ||
| Gross margin | 64.4% (better) | 35.3% |
| Operating margin | 11.4% (better) | −0.03% |
| Net margin | 5.0% | – |
| FCF margin | 9.6% | 14.3% (better) |
| Return on equity | 9.7% | – |
| Return on invested capital | 23.0% | – |
| Financial health | ||
| Debt / equity | 0.58 | – |
| Net debt / EBITDA | 0.33 (better) | 4.10 |
| Interest coverage | – | −0.0× |
| Current ratio | 0.88 | 1.55 (better) |
| Altman Z-score | 0.89 | 1.21 (better) |
| Piotroski F-score | 8 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 2.3% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 1.6% |
| Shareholder yield | 0.00% | 3.9% (better) |
| Ownership | ||
| Held by institutions | – | 91.5% |
| Held by insiders | 0.41% | 0.36% |
| Insider net buying, 12 months | −$124M | −$1.1M (better) |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 2.4% | 3.1% |
Go deeper
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
- VTRS stock overview
- VTRS income statement
- VTRS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.